Author Of 1 Presentation
P0373 - Profile of multiple sclerosis patients on treatment with ocrelizumab and socio-economic impact of the disease (ID 1735)
Abstract
Background
BACKGROUND: Multiple sclerosis (MS) is a progressive disease from the onset, independently of disease phenotype. Early treatment with highly effective disease modifying therapies (DMTs) contributes towards prevention of disease progression, hence improved quality of life of MS patients and a diminished socio-economic burden.
Objectives
OBJECTIVE: The primary objective was to assess the MS patients’ profile and treatment satisfaction from treatment with ocrelizumab; the secondary objective was to investigate the socio-economic impact of the disease.
Methods
METHODS: A retrospective analyze, under the routine clinical practice, of patients receiving ocrelizumab was conducted at University Clinic of Neurology in Skopje, excluding any personal data.
Results
RESULTS: Data was collected for 87 patients receiving ocrelizumab at our Clinic, whereby 93% were diagnosed with RMS (relapsing multiple sclerosis) and 7% with PPMS (primary progressive multiple sclerosis). 78% of the cohort were females; mean age was 38.9 years (range 19-58) and mean EDSS score was 3.9 (range 1-6). 7.4 % of RMS patients were treatment naïve, the rest were eligible for ocrelizumab as second line treatment. 49% of the patients are unemployed, whereby 28% cannot work because of MS and 37% have premature pension. 76% and 15% of the treated patients are satisfied and very satisfied from their treatment with ocrelizumab, respectively. 100% of the patients prefer to receive their treatment every six months, which results with less frequent hospital visits and increased convenience for the patient.
Conclusions
CONCLUSIONS: The use of ocrelizumab in treatment of MS patients enables an innovative approach in MS management, resulting with a high treatment satisfaction level among treated patients and diminished socio-economic burden in terms of convenience and indirect costs. Prevention of disease progression contributes towards preserving the working capacity of MS patients, which has a long-term positive impact on the society as a whole. Ocrelizumab as a highly efficient and well-tolerated DMT is becoming the standard of care for a wide spectrum of MS patients offering unprecedented benefits for quality of life improvement.